Subscribe

Xintela AB (publ) (XINT.ST)

SEK0.19 +0.00 (+1.31%)
SE STO Healthcare Biotechnology
Address Scheeletorget 1 223 81
Lund, SE
CEO Evy Lundgren-Åkerlund Assoc.Prof
Website xintela.se
IPO 2016-03-22
ISIN SE0007756903

Explore sections of this company profile

Description

Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XINMARK, a patented marker technology used to accurately identify and isolate specific stem cells that can develop into cartilage cells. Their product portfolio includes XSTEM, a stem cell-based therapy undergoing clinical trials for treating knee osteoarthritis and persistent leg ulcers. They also offer EQSTEM, another stem cell product, for managing joint conditions in horses. In oncology, Xintela is engaged in the preclinical development of therapeutic antibodies designed to combat aggressive cancers like glioblastoma, a severe brain tumor, and triple-negative breast cancer.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK0.19 +0.00 (+1.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
379.5K
Beta
1.46
Float Shares
337.25M
Free Float %
47.9%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+2.36% -9.58% -5.65% -16.54% -15.56% -25.94% -40.55% -13.20% -92.58% -94.58% -94.80%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.19
DCF (Unlevered) 0.04 -78.2%
DCF (Levered) 0.02 -92.0%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-53.56
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -45.9% Q1'26: +216.4% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -2.9% Q1'26: +12.7% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -20.5% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -2,045.8% Q1'26: -2,542.9% (vs Q1'25)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q1'26: +165.1% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +20.3% Q1'26: +22.2% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (2.02) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.04 Current price: 0.19
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
4.22M
est: 4.22M (+0.0%)
2.28M
est: 1.87M (+22.2%)
11.94M
11.94M – 11.94M
+539.5% YoY
3.42M
3.42M – 3.42M
-71.4% YoY
4.16M
4.16M – 4.16M
+21.6% YoY
55.20M
55.20M – 55.20M
+1,227.7% YoY
184.80M
184.80M – 184.80M
+234.8% YoY
EBITDA
-38.90M
est: 843.0K (-4,713.9%)
-46.08M
est: -373.4K (-12,240.2%)
-2.39M
-2.39M – -2.39M
-539.5% YoY
-684.0K
-684.0K – -684.0K
+71.4% YoY
-831.6K
-831.6K – -831.6K
-21.6% YoY
-11.04M
-11.04M – -11.04M
-1,227.7% YoY
-36.96M
-36.96M – -36.96M
-234.8% YoY
EBIT
-39.45M
est: 843.0K (-4,779.4%)
-46.68M
est: -373.4K (-12,402.4%)
-2.39M
-2.39M – -2.39M
-539.5% YoY
-684.0K
-684.0K – -684.0K
+71.4% YoY
-831.6K
-831.6K – -831.6K
-21.6% YoY
-11.04M
-11.04M – -11.04M
-1,227.7% YoY
-36.96M
-36.96M – -36.96M
-234.8% YoY
Net Income
-39.19M
est: -193.87M (+79.8%)
-48.56M
est: -41.38M (-17.3%)
-75.87M
-75.87M – -75.87M
-83.3% YoY
-234.51M
-234.51M – -234.51M
-209.1% YoY
-220.72M
-220.72M – -220.72M
+5.9% YoY
-248.30M
-248.30M – -248.30M
-12.5% YoY
-200.02M
-200.02M – -200.02M
+19.4% YoY
SGA
10.44M
est: 142.85M (-92.7%)
12.41M
est: 64.93M (-80.9%)
415.21M
415.21M – 415.21M
+539.5% YoY
118.94M
118.94M – 118.94M
-71.4% YoY
144.61M
144.61M – 144.61M
+21.6% YoY
1.92B
1.92B – 1.92B
+1,227.7% YoY
6.43B
6.43B – 6.43B
+234.8% YoY
EPS
-0.07
est: -0.34 (+79.8%)
-0.07
est: -0.06 (-17.3%)
-0.11
-0.11 – -0.11
-83.3% YoY
-0.34
-0.34 – -0.34
-209.1% YoY
-0.32
-0.32 – -0.32
+5.9% YoY
-0.36
-0.36 – -0.36
-12.5% YoY
-0.29
-0.29 – -0.29
+19.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-28 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-27 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-26 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-25 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-22 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-18 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-15 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 2/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-04-21 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C+ 2/5 3/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-33.15M
OE per share TTM
-0.05
Owner's Yield
-17.42%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
521.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-22.2K
Shares Outstanding
703.36M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Evy Lundgren-Åkerlund Assoc.Prof Chief Executive Officer 4M —
Gregory Batcheller Executive Chairman of the Board 383.0K male
Lucienne Vonk Chief Scientific Officer — female
Per Goran Oskar Norlen Chief Medical Officer — —
Peter Ekolind Chief Operating Officer & Vice President of Commercial Manufacturing — male
Gunnar Telhammar Chief Financial Officer & Finance Director — male
Camilla Wennersten Director of Clinical Development — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology